Ascendis Pharma A/S Financials

Market Capitalization $10.54 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	-26.67
Forward PE	-44.10
Price to Sales TTM	$28.58
Price to Book MRQ	$-55.08
Enterprise to Revenue	29.16
Enterprise to EBITDA	-32.69

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	-92.67%
Operating Margin	-103.23%
Return on Assets TTM	-22.39%
Return on Equity TTM	357.68%

Income Statement

Revenue TTM	$433,500,191
Revenue per Share TTM	$6.28
Quarterly Revenue Growth	5.30%
Gross Profit TTM	$369,767,505
EBITDA	$-386,618,354
Net Income to Common TTM	$-401,724,390
Diluted EPS TTM	$-6.86
Quarterly Earnings Growth YoY	5.28%

Balance Sheet

Total Cash MRQ	$608,947,976
Total Cash per Share MRQ	$8.58
Total Debt MRQ	$
Total Debt to Equity MRQ	-5.25
Current Ratio MRQ	1.04
Book Value per Share MRQ	$-3.14

Cash Flow

Operating Cash Flow TTM	$-257,404,596
Levered Free Cash Flow TTM	$-156,886,643

ASND Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	59,843,600
Float Shares	59,902,597
Avg 10 Volume	409,390
Avg 30 Volume	None
Shares Short	2,693,234
Short Ratio	6.49
Short % of Shares	5.35%
% Held by Insiders	0.78%
% Held by Institutions	113.57%

Stock Price Summary

Beta	0.36
Fifty Two Week Low	$111.09
Fifty Two Week High	$183.00
Fifty Two Week Change	22.03%
Day 50 MA	$167.18
Day 200 MA	$146.11

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date